Lastres-Becker Isabel, Porras Gracia, Arribas-Blázquez Marina, Maestro Inés, Borrego-Hernández Daniel, Boya Patricia, Cerdán Sebastián, García-Redondo Alberto, Martínez Ana, Martin-Requero Ángeles
Instituto de Investigaciones Biomédicas "Alberto Sols" UAM-CSIC, Arturo Duperier 4, 28029 Madrid, Spain.
Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid, Arturo Duperier 4, 28029 Madrid, Spain.
Int J Mol Sci. 2021 Mar 16;22(6):3007. doi: 10.3390/ijms22063007.
Amyotrophic lateral sclerosis (ALS) is a fatal neurological condition where motor neurons (MNs) degenerate. Most of the ALS cases are sporadic (sALS), whereas 10% are hereditarily transmitted (fALS), among which mutations are found in the gene that codes for the enzyme superoxide dismutase 1 (SOD1). A central question in ALS field is whether causative mutations display selective alterations not found in sALS patients, or they converge on shared molecular pathways. To identify specific and common mechanisms for designing appropriate therapeutic interventions, we focused on the -mutated (-ALS) versus sALS patients. Since ALS pathology involves different cell types other than MNs, we generated lymphoblastoid cell lines (LCLs) from sALS and -ALS patients and healthy donors and investigated whether they show changes in oxidative stress, mitochondrial dysfunction, metabolic disturbances, the antioxidant NRF2 pathway, inflammatory profile, and autophagic flux. Both oxidative phosphorylation and glycolysis appear to be upregulated in lymphoblasts from sALS and -ALS. Our results indicate significant differences in NRF2/ARE pathway between sALS and -ALS lymphoblasts. Furthermore, levels of inflammatory cytokines and autophagic flux discriminate between sALS and -ALS lymphoblasts. Overall, different molecular mechanisms are involved in sALS and -ALS patients and thus, personalized medicine should be developed for each case.
肌萎缩侧索硬化症(ALS)是一种运动神经元(MNs)退化的致命性神经疾病。大多数ALS病例为散发性(sALS),而10%为遗传性(fALS),其中在编码超氧化物歧化酶1(SOD1)的基因中发现了突变。ALS领域的一个核心问题是,致病突变是否表现出散发性ALS患者未发现的选择性改变,或者它们是否汇聚于共同的分子途径。为了确定设计适当治疗干预措施的特异性和共同机制,我们重点研究了突变型(-ALS)与散发性ALS患者。由于ALS病理涉及运动神经元以外的不同细胞类型,我们从散发性ALS和突变型ALS患者以及健康供体中生成了淋巴母细胞系(LCLs),并研究它们是否在氧化应激、线粒体功能障碍、代谢紊乱、抗氧化剂NRF2途径、炎症特征和自噬通量方面表现出变化。散发性ALS和突变型ALS的淋巴母细胞中氧化磷酸化和糖酵解似乎均上调。我们的结果表明,散发性ALS和突变型ALS淋巴母细胞在NRF2/ARE途径上存在显著差异。此外,炎症细胞因子水平和自噬通量可区分散发性ALS和突变型ALS淋巴母细胞。总体而言,散发性ALS和突变型ALS患者涉及不同的分子机制,因此,应针对每个病例制定个性化医疗方案。